Ratings by Evercore ISI (Umer Raffat)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/25/2026 | Apnimed Inc. | APMD | New Coverage | Outperform (N/A) |
25.63 (16.60) |
-35.23% | Details | |
| 8/14/2026 | Alvotech SA | ALVO | New Coverage | Outperform (N/A) |
4.09 (5.03) |
22.98% | Details | |
| 7/6/2026 | Parabilis Medicines | PBLS | New Coverage | Outperform (N/A) |
29.58 (25.35) |
-14.3% | Details | |
| 5/14/2026 | Biogen | BIIB | New Coverage | Outperform (N/A) |
204.53 (233.48) |
14.15% | Details | |
| 5/12/2026 | Kailera Therapeutics | KLRA | New Coverage | Outperform (N/A) |
22.93 (11.43) |
-50.15% | Details | |
| 1/6/2026 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2025 | Organon & Co. | OGN | Downgrade | In Line (Outperform) |
12.93 (13.75) |
6.34% | Details | |
| 2/25/2025 | Metsera Inc | MTSR | New Coverage | Outperform (N/A) |
29.81 (70.50) |
136.5% | Details | |
| 7/16/2024 | Spyre | SYRE | New Coverage | Outperform (N/A) |
28.80 (84.72) |
194.17% | Details | |
| 6/14/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | In Line (Outperform) |
18.97 (27.33) |
44.07% | Details | |
| 2/28/2024 | Fractyl Health Inc | GUTS | New Coverage | Outperform (N/A) |
9.12 (1.38) |
-84.87% | Details | |
| 2/16/2024 | Rapt Therapeutics | RAPT | New Coverage | Outperform (N/A) |
25.54 (58.02) |
127.17% | Details | |
| 10/24/2023 | Alkermes | ALKS | Upgrade | Outperform (In Line) |
24.43 (42.97) |
75.89% | Details | |
| 7/17/2023 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/21/2023 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
5.50 (40.50) |
636.36% | Details | |
| 5/30/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/18/2023 | Teva Pharma | TEVA | Upgrade | Outperform (In Line) |
8.13 (41.31) |
408.12% | Details | |
| 5/11/2023 | Phathom Pharmaceuticals | PHAT | Upgrade | Outperform (In Line) |
12.43 (7.01) |
-43.6% | Details | |
| 3/7/2023 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Outperform (N/A) |
18.96 (20.92) |
10.34% | Details | |
| 2/9/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2023 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Legend Biotech Corp. | LEGN | New Coverage | Outperform (N/A) |
49.82 (18.65) |
-62.57% | Details | |
| 9/13/2022 | Cerevel Therapeutics | CERE | New Coverage | Outperform (N/A) |
31.08 (44.96) |
44.66% | Details | |
| 5/6/2022 | Phathom Pharmaceuticals | PHAT | Downgrade | In Line (Outperform) |
13.07 (7.01) |
-46.37% | Details | |
| 2/2/2022 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Outperform (N/A) |
23.18 (18.97) |
-18.16% | Details | |
| 6/10/2021 | Organon & Co. | OGN | New Coverage | Outperform (N/A) |
28.45 (13.75) |
-51.67% | Details | |
| 3/12/2021 | Kodiak Sciences Inc. | KOD | New Coverage | Outperform (N/A) |
126.89 (91.35) |
-28.01% | Details | |
| 12/8/2020 | Mirati Therapeutics | MRTX | New Coverage | Outperform (N/A) |
233.26 (58.70) |
-74.83% | Details | |
| 11/25/2020 | Atea Pharmaceuticals | AVIR | New Coverage | Outperform (N/A) |
34.07 (4.39) |
-87.11% | Details | |
| 11/23/2020 | Arcus Biosciences | RCUS | New Coverage | Outperform (N/A) |
24.38 (22.14) |
-9.19% | Details | |
| 7/14/2020 | Royalty Pharma | RPRX | New Coverage | In Line (N/A) |
47.64 (60.27) |
26.51% | Details | |
| 1/21/2020 | Amgen | AMGN | Upgrade | Outperform (In Line) |
241.49 (424.94) |
75.97% | Details | |
| 11/20/2019 | Phathom Pharmaceuticals | PHAT | New Coverage | Outperform (N/A) |
24.27 (7.01) |
-71.12% | Details | |
| 8/7/2019 | Teva Pharma | TEVA | Downgrade | In Line (Outperform) |
7.06 (41.31) |
485.13% | Details | |
| 7/2/2019 | Dova Pharmaceuticals Inc | DOVA | Upgrade | Outperform (In Line) |
14.10 (28.04) |
98.87% | Details | |
| 1/28/2019 | Amgen | AMGN | Downgrade | In Line (Outperform) |
200.97 (241.49) |
20.16% | Details | |
| 11/16/2018 | Molecular Templates | MTEM | New Coverage | Outperform (N/A) |
4.40 (0.11) |
-97.5% | Details | |
| 8/24/2018 | Mylan | MYL | Upgrade | Outperform (In Line) |
37.86 (15.86) |
-58.11% | Details | |
| 8/13/2018 | Teva Pharma | TEVA | Maintain | Outperform (N/A) |
|
Details |
